• fluoxetine;
  • prednisolone;
  • cortisol;
  • glucocorticoids;
  • selective serotonin reuptake inhibitors;
  • CYP3A4 isoenzyme inhibitors

Study Objective. To evaluate the potential effect of fluoxetine, a cytochrome P450 isoenzyme inhibitor, on prednisolone disposition and cortisol suppression.

Design. Sequential, two-phase, crossover, open-label pharmacokinetic study.

Setting. General clinical research center.

Subjects. Fourteen healthy volunteers.

Intervention. A single intravenous dose of prednisolone 40 mg before and after 14 days of treatment with fluoxetine 20 mg/day for 5 days followed by 60 mg/day for 9 days to achieve steady-state concentrations.

Measurements and Main Results. Pharmacokinetic parameters of the prednisolone and resulting pharmacodynamic effects on the time course of plasma cortisol suppression before and after fluoxetine administration were evaluated. No significant differences were observed for the mean ± SD area under the prednisolone concentration–time curve (3739 ± 992 vs 3498 ± 797 μg·hr/L, respectively), clearance (8.58 ± 2.62 vs 8.92 ± 2.05 L/hr, respectively), volume of distribution (39.5 ± 12.4 vs 38.2 ± 9.9 L, respectively), elimination half-life (3.32 ± 0.83 vs 3.05 ± 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 ± 3.1 vs 22.0 ± 4.2 hrs, respectively).

Conclusion. Fluoxetine administration did not significantly affect prednisolone disposition or prolong cortisol suppression. This finding suggests that coadministration of these agents is unlikely to result in clinically important pharmacokinetic or pharmacodynamic drug interactions. Prednisolone may be a useful alternative for patients who require both glucocorticoid and fluoxetine therapy.